GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Teleflex Inc (NYSE:TFX) » Definitions » Cash And Cash Equivalents

Teleflex (Teleflex) Cash And Cash Equivalents

: $223 Mil (As of Dec. 2023)
View and export this data going back to 1994. Start your Free Trial

Teleflex's quarterly cash and cash equivalents increased from Jun. 2023 ($250.82 Mil) to Sep. 2023 ($881.50 Mil) but then stayed the same from Sep. 2023 ($881.50 Mil) to Dec. 2023 ($222.85 Mil).

Teleflex's annual cash and cash equivalents declined from Dec. 2021 ($445.08 Mil) to Dec. 2022 ($292.03 Mil) and declined from Dec. 2022 ($292.03 Mil) to Dec. 2023 ($222.85 Mil).


Teleflex Cash And Cash Equivalents Historical Data

The historical data trend for Teleflex's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teleflex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 301.08 375.88 445.08 292.03 222.85

Teleflex Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash And Cash Equivalents Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 292.03 264.14 250.82 881.50 222.85

Teleflex Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Teleflex  (NYSE:TFX) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Teleflex Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Teleflex's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Teleflex (Teleflex) Business Description

Traded in Other Exchanges
Address
550 East Swedesford Road, Suite 400, Wayne, PA, USA, 19087
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2022 sales), interventional (16%), anesthesia (14%), surgical (14%), interventional urology (12%), original-equipment manufacturing (10%), and all other (10%). Geographic exposure for the business is primarily in the U.S., which accounts for 60% of revenue, with international markets making up the remainder.
Executives
Liam Kelly officer: EVP & President, International IDA BUSINESS AND TECHNOLOGY PARK, DUBLIN ROAD, ATHLONE L2 00000
Thomas E Powell officer: Senior Vice President & CFO C/O TOMOTHERAPY INCORPORATED, 1240 DEMING WAY, MADISON WI 53717
Stuart A Randle director 585 WEST 500 SOUTH, BOUNTIFUL UT 84010
Jaewon Ryu director 950 N. GLEBE ROAD, SUITE 700, ARLINGTON VA 22203
Neena M Patil director JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304
Andrew A Krakauer director CANTEL MEDICAL CORP., 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Cameron P Hicks officer: Vice President, Global HR 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
Klasko Stephen K. M.d. director 155 SOUTH LIMERICK ROAD, LIMERICK PA 19468
Jay White officer: VP & Pres, Global Commercial 3015 CARRINGTON MILL BLVD., MORRISVILLE NC 27560
Daniel V. Logue officer: VP, Gen Counsel & Secretary 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
John Deren officer: VP & Chief Accounting Officer 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
James J Leyden officer: VP, General Counsel, Secretary C/O INFRASOURCE SERVICES, INC, 500 WEST DUTTON MILL ROAD, ASTON PA 19014
James Winters officer: Vice President, Mfg and Supply 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
Mario Wijker officer: Vice President, QARA 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
Benson Smith director C/O ROCHESTER MEDICAL INC, ONE ROCHESTER MEDICAL DDRIVE, STEWARTVILLE MN 55976